New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
12:31 EDTCELG, GIS, ULTA, CTB, SBUX, GMCR, AROOn The Fly: Midday Wrap
Stocks on Wall Street traded in a narrow band on either side of the flat-line in the early going, as the news flow continues to be dominated by developments between Russia and Ukraine. Stocks opened in quiet fashion and moved to the upside early in the session. The market was unable to hold its gains, however, and reversed course following a report that indicated that consumer sentiment has fallen this month. The averages crossed back into positive territory right before noon, but the market has remained in a narrow range throughout the morning's swings. ECONOMIC EVENTS: In the U.S., producer prices fell 0.1% overall in February, versus an expected increase of 0.2%. The core reading, which excludes food and energy, fell 0.2%, versus an expected increase of 0.1%. The Reuters/University of Michigan Consumer Sentiment Survey for March unexpectedly dropped to a four-month low of 79.9. The preliminary reading for the month was expected by analysts to have come in at 81.8, which would have been a slight bump from the prior 81.6 figure. In Europe, one person reportedly died and several were injured after violent clashes in the Ukrainian city of Donetsk amid demonstrations from those opposed to Russia’s military intervention in Crimea. Also, reports indicated the Russian military conducted another military exercise near Ukraine on Thursday. COMPANY NEWS: Shares of single-serve coffee machine maker Keurig Green Mountain (GMCR) rose nearly 9% after the company agreed to new terms in its deal with coffee giant Starbucks (SBUX). Research firm Buckingham said its views Keurig's amended deal with Starbucks as a positive event for both companies. The new agreement lets Keurig pursue additional premium unlicensed brands and provides Starbucks an opportunity for better margins, said the firm... Shares of teen retailer Aeropostale (ARO) fell almost 14% after its fourth quarter results and first quarter outlook missed analysts' consensus expectations. The retailer also entered a financing deal with private equity firm Sycamore Partners for a strategic partnership and $150M in senior secured credit facilities. Aeropostale will also issue convertible preferred stock to Sycamore that gives the firm the right to acquire up to 5% of the company's common stock at an exercise price of $7.25, the closing price of the company's common stock on March 12. MAJOR MOVERS: Among the notable gainers was beauty retailer Ulta Salon (ULTA), which advanced over 7% after the company’s fourth quarter results beat estimates. Also higher following its quarterly earnings report was tire maker Cooper Tire & Rubber (CTB), which rose nearly 8%. Among the noteworthy losers was Celgene (CELG), which dropped almost 3% after the U.K.'s healthcare guidance body issued new draft guidance on the use of the company's Revlimid drug. Also lower were shares of cereal and packaged foods maker General Mills (GIS), which slid 2% after the company warned its third quarter earnings could miss expectations. INDEXES: Near midday, the Dow was up 1.15, or 0.01%, to 16,110.04, the Nasdaq was up 1.74, or 0.04%, to 4,262.16, and the S&P 500 was virtually unchanged at 1,846.36.
News For GMCR;SBUX;ARO;ULTA;CELG;CTB;GIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 10, 2014
10:20 EDTULTAOptions with decreasing implied volatility
Subscribe for More Information
December 9, 2014
14:10 EDTCELGCelgene ISTODAX combination demonstrates complete response in 51% of patients
Subscribe for More Information
08:34 EDTCELGCelgene price target raised to $130 from $102 at Argus
Argus hiked its price target on Celgene as the firm thinks the company posted solid Q3 results, while it is continuing to make progress in its pipeline. Argus keeps a Buy rating on the shares.
08:28 EDTCELGCelgene price target raised to $130 from $112 at UBS
Subscribe for More Information
07:44 EDTCELGAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
05:46 EDTCELGCelgene presents POMALYST/IMNOVID Phase IIIb study results at ASH meeting
Celgene announced that results from the STRATUS trial, a single-arm phase IIIb study of pomalidomide plus low-dose dexamethasone in patients with relapsed and refractory multiple myeloma were presented at the 56th American Society of Hematology annual meeting. Pomalidomide is marketed as POMALYST in the United States and IMNOVID in the European Union. In the study, 599 patients with refractory, or relapsed and refractory, disease who had previously failed lenalidomide and bortezomib had been enrolled at the time of the data cutoff. The primary endpoint was safety, and key secondary endpoints included pomalidomide exposure, overall response rate, or ORR, duration of response, or DOR, progression-free survival, or PFS, overall survival, or OS, and cytogenetic analyses. Patients had a median five prior therapies. All patients received thromboprophylaxis with low-dose aspirin, low-molecular-weight heparin, or equivalent. At a median follow-up of 6.8 months with a median four cycles received, the median PFS and OS were 4.2 months and 11.9 months, respectively. The ORR was 35%, with 8% of patients achieving at least a very good partial response, or VGPR. The median DOR was 6.8 months. In patients refractory to prior lenalidomide or lenalidomide and bortezomib, similar PFS, OS, and ORR were achieved.
05:22 EDTCELGCelgene reports REVLIMID study data suggests improved response rates, PFS, OS
Subscribe for More Information
05:17 EDTCELGCelgene reports Vidaza Phase III study shows doubled overall survival times
Subscribe for More Information
December 8, 2014
14:06 EDTCELGCelgene reports luspatercept, sotatercept increased hemoglobin levels in trials
Subscribe for More Information
13:54 EDTCELGCelgene announces results from phase lll Revlimid study
Subscribe for More Information
10:20 EDTULTAOptions with decreasing implied volatility
Subscribe for More Information
07:52 EDTSBUXStarbucks price target raised to $97 from $88 at Jefferies
Subscribe for More Information
07:36 EDTCELGAgios announces Celgene to extend discovery phase of collaboration to April 2016
Agios Pharmaceuticals (AGIO) announced that Celgene (CELG) has elected to extend the period of its exclusivity for an additional year to April 2016 under the global strategic collaboration agreement. The two companies have been working together since April 2010 to discover, develop and commercialize disease-altering therapies in oncology arising from Agios' cancer metabolism research platform. The terms of the collaboration extension are consistent with previously agreed upon financial terms. As a result of the extension, Celgene will maintain its exclusive option to drug candidates that emerge from Agios' cancer metabolism research platform through April 2016. Agios will receive a $20M payment. Following this extension, the discovery portion of the collaboration will expire on April 14, 2016. Under the terms of the original agreement announced in April 2010, Agios leads research, preclinical and early development efforts through Phase 1, while Celgene receives an option to obtain exclusive rights either upon IND acceptance or at the end of Phase 1, to further development and commercialize medicines emerging from Agios' cancer metabolism research. Celgene would lead and fund global development and commercialization of some of these drugs, and Agios would retain development and commercialization rights for certain drugs in the United States. On all programs, Agios is eligible to receive up to $120M in milestone-based payments as well as royalties on any sales.
07:17 EDTCELGCelgene price target raised to $131 from $120 at Cantor
Subscribe for More Information
06:47 EDTSBUXStarbucks coverage resumed with a Conviction Buy at Goldman
Subscribe for More Information
05:35 EDTCELGCelgene REVLIMID, low-dose dexamethasone increased PFS
Subscribe for More Information
December 7, 2014
16:40 EDTCELGAgios announces new data from Ongoing Phase 1 trial of AG-221
Subscribe for More Information
14:10 EDTCELGAmerican Society of Hematology to hold a meeting
Subscribe for More Information
13:16 EDTCELGCelgene, Acceleron announced data from luspatercept phase 2 clinical trial
Subscribe for More Information
December 6, 2014
09:28 EDTCELGCelgene to hold an analyst and investor event
Analyst and Investor Event being held in conjunction with the American Society of Hematology's 56th Annual Meeting in San Francisco on December 7 at 11 pm. Webcast Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use